Title : Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.

Pub. Date : 2013 May

PMID : 23386687






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. INK128 mechanistic target of rapamycin kinase Mus musculus
2 Marked reduction in activation of mTOR complex (mTORC)1 and blockade of cell growth was seen with both drugs, whereas only MLN0128 treatment had effects in blocking mTORC2 and 4EBP1 phosphorylation. INK128 CREB regulated transcription coactivator 2 Mus musculus
3 Marked reduction in activation of mTOR complex (mTORC)1 and blockade of cell growth was seen with both drugs, whereas only MLN0128 treatment had effects in blocking mTORC2 and 4EBP1 phosphorylation. INK128 eukaryotic translation initiation factor 4E binding protein 1 Mus musculus
4 Differences in side-effect profiles might make MLN0128 more attractive for treatment of patients with TSC-related tumors, but will require additional study in humans. INK128 TSC complex subunit 1 Mus musculus